Back to Search Start Over

miR-638 suppresses cervical cancer progression by inhibiting NCAPG2 under the treatment of Tetrandrine.

Authors :
Wang M
Liu K
Zhou Z
Geng H
Source :
Histology and histopathology [Histol Histopathol] 2024 Apr; Vol. 39 (4), pp. 497-509. Date of Electronic Publication: 2023 Aug 04.
Publication Year :
2024

Abstract

Background: The interaction of microRNA with Chinese herbal medicines is a promising therapeutic approach for prevention of cervical cancer.<br />Methods: Western blotting or qRT-PCR were carried out to identify the expression of NCAPG2 and miR-638. A tetrandrine (TET) cell model was used to explore the effects of miR-638 and its target gene NCAPG2 using CCK-8, transwell, wound healing, and western blot assays. Furthermore, luciferase activity assay was conducted to measure the interaction among TET, NCAPG2 and miR-638.<br />Results: Under TET treatment, Hela and SiHa cells exhibited repressed cell viability, migration, invasion, and epithelial-mesenchymal transition (EMT), and these effects were further enhanced by high expression of miR-638. In contrast, NCAPG2 expression was low in TET-treated cells and had an opposite effect to that of miR-638.<br />Conclusion: We highlighted that miR-638 suppresses cervical cancer progression by inhibiting NCAPG2 under tetrandrine treatment.<br /> (©The Author(s) 2024. Open Access. This article is licensed under a Creative Commons CC-BY International License.)

Details

Language :
English
ISSN :
1699-5848
Volume :
39
Issue :
4
Database :
MEDLINE
Journal :
Histology and histopathology
Publication Type :
Academic Journal
Accession number :
37702425
Full Text :
https://doi.org/10.14670/HH-18-657